October 5, 2017
FDA issues Safety Alert for intraocular TMV injections
Editor's Note
The Food & Drug Administration (FDA) on October 3 issued a Safety Alert saying the agency had received an adverse event report on a patient who was diagnosed with bilateral hemorrhagic occlusive retinal vasculitis after being administered injections of a compounded triamcinolone, moxifloxacin, vancomycin (TMV) formulation in each eye at the end of cataract surgery procedures that were done 2 weeks apart.
The TMV formulation was compounded by Imprimis Pharmaceuticals (Ledgewood, New Jersey).
Free Daily News
- Study: Systemic gender bias embedded in surgical practice
- Literature review: Endoscope disinfection failures highlight need for stronger sterilization practices
- Study: GLP-1 drugs heighten risk of gastric residue but not perioperative pulmonary aspiration
- OAS CAHPS compliance soars to 96% among ASCs, vendor satisfaction also improves
- Knee surgical robot market set to surge, projected to reach $5.9B by 2032
- Health system mega-mergers fall short amid cost, quality concerns
- Health systems boost security spending as workplace violence escalates
- Strengthening healthcare cyber defenses challenged by third-party, asset-related risks
- Healthcare’s “Blockbuster Moment:” Dr Dan Weberg to deliver opening keynote address at OR Manager Conference
- Hospital staffing report: Nurse turnover eases but vacancies, costs remain high
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement